Akeso's ivonescimab achieves milestones in lung cancer and NPC treatment

Akeso, Inc. (HKEX:9926) has announced significant progress in the development and approval of its key drug candidates, ivonescimab and anniko. The AK112-306/HARMONI-6 Phase III clinical trial demonstrated that ivonescimab, combined with chemotherapy, achieved its primary endpoint, showing superior progression-free survival (PFS) compared to tislelizumab plus chemotherapy in first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). Results from the HARMONI-6 trial were statistically significant and clinically meaningful.